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A 7-year follow-up of sacral anterior root stimulation for bladder control in
patients with a spinal cord injury: quality of life and users’ experiences
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Spectrum Twente, Enschede, The Netherlands
Study design: Cross-sectional descriptive study.
Objectives: To assess long-term effects and quality of life (QoL) of using sacral anterior root
stimulation (SARS) in spinal cord injured patients.
Setting: Neurosurgical and Urological Departments of a large teaching hospital and a large
rehabilitation centre in the Netherlands.
Methods: In all, 42 patients with complete spinal cord injury (SCI) implanted between 1987 and
2000 were included. A questionnaire was constructed to determine complications, technical
failures and personal experiences of the patients. The Qualiveen questionnaire was used and the
outcome was compared with data obtained from a reference group of 400 SCI patients with
neurogenic bladder problems not using the bladder controller. The Qualiveen questionnaire
measures disease-specific aspects in four domains with respect to limitations, constraints, fears
and feelings and general QoL aspects, suitable for use in SCI patients with urinary disorders.
Results: The results of 37 patients are presented. Our results with the bladder controller with
respect to medical and technical complications and infection rates are similar to the results
presented by others. From users’ experiences, the most important advantages reported were a
decreased infection rate (68%), improved social life (54%) and continence (54%). Comparison
of the obtained results of our patient group with the Qualiveen questionnaire with a reference
group not using the bladder controller indicates that the specific impact of urinary disorders in
the four domains on QoL is reduced and that general QoL is improved.
Conclusion: SARS is effective and safe for neurogenic bladder management in patients with
complete SCI. Users’ experiences are positive. Furthermore, this therapy seems to reduce the
effects of urinary-disorder-specific QoL aspects, and to increase the QoL in general.
Spinal Cord (2003) 41, 397–402. doi:10.1038/sj.sc.3101465
Keywords: spinal cord injury; sacral anterior root stimulation; neurogenic bladder; quality
of life
Introduction/background
In the last 30 years considerable progress has been made
in the urological rehabilitation of patients with neuro-
genic bladder disorders as a result of a spinal cord injury
(SCI). Nevertheless, these patients frequently develop
complications such as urinary tract infections, stones of
the upper and the lower urinary tract and deterioration
of the bladder. Furthermore, upper urinary tract
problems can be caused because of reflux and/or
obstruction, increasing the risk of deterioration of
kidney function. Incontinence remains another impor-
tant problem for these patients.1
The management of neurogenic bladder dysfunction
after SCI in general consists of increasing bladder
capacity, maintaining low-pressure storage of urine with
preservation of the upper urinary tract and preventing
incontinence. In addition, bladder management aims
at full evacuation of urine to reduce the incidence of
urinary tract infections. In patients with complete SCI at
a level that leaves the sacral segments intact, detrusor
hyper-reflexia generally develops after a phase of spinal
shock. This type of bladder dysfunction can cause
important morbidity. Anticholinergic therapy is the
usual treatment but is often insufficient.1–3
In the 1970s, Brindley developed the sacral anterior
root stimulator (SARS) for complete SCI patients with
severe neurogenic bladder disorders. The device was
implanted in the first patient in 1976.4,5 Nowadays
SARS is usually combined with posterior sacral root
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rhizotomy, eliminating all reflex activity of the detrusor
and thereby increasing bladder capacity and controlling
reservoir function of the bladder. Stimulation of the
efferent nerves (anterior roots) produces a contraction
of both the detrusor and the sphincter muscle. Voiding
is possible upon intermittent stimulation because
the striated muscle of the sphincter contracts and
relaxes more rapidly than the smooth muscle of the
detrusor.2
In the literature, remarkable results of SARS for
management of both urinary and faecal incontinence
in SCI patients are reported. Short-term results have
shown that 85–97% of the patients use their implants
regularly for micturition and 55–70% to assist defaeca-
tion. Complete continence is reported in 68–91%.
In male patients 41–71% reported full implant-driven
erections, sufficient for coitus in 26–55%.2,6–11 A
substantial decrease in symptomatic urinary tract
infection has been reported by many groups (65–71%
have had no urinary tract infection in the previous year
after implantation6,9). Side effects, for example, pain,
increased spasms, loss of reflex erection or occasionally
autonomic dysreflexia on stimulation, are rare.6–14
Implant failures of the internal equipment are reported
in 14.4% of users.15
Few studies have reported on the experiences of the
users and effects of the bladder controller on the quality
of life (QoL). Kachourbos and Creasey16 showed an
improvement in QoL using a self-made structured
questionnaire. Wielink et al14 used the Nottingham
Health Profile, a generic measure covering the dimen-
sions of physical mobility, pain, energy, sleep, emotional
reaction and social isolation, but did not show
significant improvement after implantation of the
bladder stimulation. The subscales ‘pain’ and ‘physical
mobility’ appeared to be inapplicable in SCI patients, as
several items relate to difficulties experienced in walking
and standing. The Karnofsky Performance Index to
quantify ‘objective’ QoL aspects in cancer research did
not show significant improvement either. The fact that
drainage of the bladder is just one of the many problems
that patients with a SCI experience, may explain
these small effects on QoL. However, overall well being
as assessed with the Affect Balance Scale, did improve
significantly with SARS. Wielink et al14 used a
self-constructed questionnaire to assess the degrees of
experienced bothersomeness caused by bladder pro-
blems, urinary incontinence and micturition problems
(on performing household work, shopping, odd
jobs about the house, sports and going out) on
QoL, this showed significant improvement using
SARS.
A limitation reported in all studies is the measured
QoL for these SCI patients, because validated disease-
specific instruments available for this purpose alone
were lacking. The majority of existing questionnaires is
generic and not responsive to detect changes in QoL in
SCI patients. In addition, the impact on QoL of urinary
disorders in these patients remained unknown. In order
to address this need, the Qualiveen questionnaire was
developed for use in SCI patients with urinary
disorders.17
The objective of this study is to determine the long-
term results of the implanted bladder controller in SCI
patients with respect to effectiveness, side effects,
complications and advantages. Furthermore, this study
intends to determine the users’ experiences, and to gain
experience with the newly developed Qualiveen ques-
tionnaire for measuring QoL.
Methods
A cross-sectional descriptive study was conducted.
The study was approved by the local Medical Ethics
Committee. All patients gave their informed consent.
In all, 42 patients were recruited from a database at the
Rehabilitation Centre Het Roessingh. All patients were
implanted at the Neurosurgical Department of Hospital
Medical Spectrum Twente (Enschede, The Netherlands)
between 1987 and 2000. Most of our patients have been
included in the study of the Dutch Study Group on
SARS published in 1997, and therefore the selection
criteria for implantation were equal with those men-
tioned in other publications.3 Four patients had died
of unrelated causes. One patient did not respond on our
request. The patient characteristics are described in
Table 1.
A questionnaire was constructed to determine the
complications, technical failures and personal experi-
ences of the patients with the bladder controller. The
items addressed were related to expectations, advantages
and disadvantages, recommendation to future patients
and willingness to undergo the implant procedure again
with their present knowledge. Patients’ medical records
were used to complete the data.
A bladder disease-specific questionnaire, that is, the
Qualiveen questionnaire of Coloplast (Laboratoires
Coloplast, Cedex, France), was used. We used the
official Dutch version which was cross-translated by
Coloplast. This questionnaire is composed of two parts.
The first part measures the specific impact of urinary
problems (SIUP) in four scales, that is, limitations (eg
are you bothered by urine leaks during the day?),
constraints (eg can you go out without planning in
Table 1 Characteristics of the population
Gender 32 male and five female
Age at questionnaires (years) 43 (23–63)a
Time postinjury (months) 73 (46–498)a
Time between injury and
implantation (months)
87 (11–471)a
Follow-up (months) 86 (16–159)a
Level of injury 14 tetraplegic
23 paraplegic
Actual use 89%
aMeans (range)
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advance?), fears (eg do you worry about smelling of
urine?) and feelings (eg do you feel embarrassed because
of your bladder problems?). The scores of the four scales
range between 0 and 4 (not at all, slightly, moderately,
quite a bit or extremely) meaning urinary disorders
do have low (0) or high (4) impact. The mean of
these four scales is calculated and results in the mean
SIUP.
The second part of the questionnaire measures the
QoL of SCI patients using nine questions starting with
the statement ‘You feel things are goingy’. In order to
obtain a disease-specific questionnaire, questions on
standing and walking are no elements of the ques-
tionnaire. The answers range from very badly to very
well (2 to +2). The mean score is calculated resulting
in the QoL index; low scores indicate poor QoL and
high scores indicate better QoL.
To compare our results as best as possible, we
compared our scores with the scores of a group of 400
French SCI patients with neurogenic bladder problems
reported in the manual of the Qualiveen questionnaire.
None of these patients use SARS. We tried to obtain the
crude data of this group to be able to match our patients
with these reference data. However, after several
requests we did not receive a respond and decided to
use the data from the manual.18
Statistical analysis
A nonparametric test, the Mann–Whitney U-test, was
used to analyse the differences of the median scores of
the SIUP in the four scales, the overall index and the
QoL index between the study group and the reference
group.
Results
The. characteristics of 37 patients are presented in
Table 1. The mean age was 43 years. The mean follow-
up was 7 years with a range from 1 to 13 years. Table 2
describes the different methods of bladder management
the patients used before the implant of the bladder
controller; most patients used percussion and about one-
third intermittent self-catheterisation.
Of the 37 patients, 32 (87%) still use the bladder
controller for urinary control with a mean micturition
frequency of four times a day. In all, 22 (60%) patients
present a clear benefit in the evacuation of stools.
Of the 32 male patients, 20 (65%) were able to achieve
a stimulation-driven erection, but none of them
have used it for coitus. The erection is considered
particularly useful when attaching a condom for urine
drainage.
Complete urinary continence was achieved in 57% of
the patients during the day and 70% at night. An overall
improvement in urinary continence was found in 73%,
while some patients (16%) only experienced mild stress
incontinence.
Figure 1 shows the incidence of urinary tract
infections requiring treatment with antibiotics before
implantation and after long-term use. The results show
that the infection rate decreased dramatically with the
use of the bladder stimulator. About 87% of the patients
experienced a reduction in urinary tract infections with
SARS. In 16 (41%) patients, urinary tract infections were
not seen again after implantation.
Patients’ experiences and expectations
Before implantation, the majority of the patients
expected to achieve complete continence and expected
a decrease in urinary tract infections.. Table 3 presents
the patients expectations about the bladder controller
before implantation. With respect to micturition these
expectations were met in 62% and partially met in 32%,
and for defaecation in 38% (partial in 30%). The male
patients’ expectations about the possibility to have
stimulated erections were met in 47%.
Table 2 Bladder management before the implant of the
bladder controller (n=36)
%
Percussion 67
Intermittent self-catheterisation 31
Intermittent catheterisation by others 8
Indwelling catheter 8
Other 3
Figure 1 Urinary tract infection rates prior to implantation
and after long-term use of the bladder controller
Table 3 Expectations before implantation (n=37)
%
Decrease of urinary tract infections 84
Continence 76
Less time for defecation 35
Independence 32
Erection 27
Less time for micturition 19
Other 11
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Table 4 presents the experiences with respect to
advantages and disadvantages of the bladder controller.
The main advantages mentioned are a decrease in
urinary tract infections, an improvement in social life
and achieved continence. About one-third did not
experience disadvantages because of the implant,
another third mentioned several different disadvantages
like loss of ejaculation (two), a dependency on a
technical device (two) and appearance of spasm while
stimulating (one).
In 92%, the implanted bladder controller has had
positive influence on several aspects in life. Almost 90%
of patients would chose again for surgery and nearly the
same amount would recommend the bladder controller
to other patients with neurogenic bladder dysfunction.
Complications and technical failures
In three patients the bladder controller never func-
tioned, in two of these patients because of fibrosis
around the sacral roots and in one patient probably by
S3 and S4 root failure. However, the latter patient did
reach complete continence because of deafferentation.
Postoperative leakage of cerebro-spinal fluid (CSF)
and neuropraxia both occurred once. Detrusor weak-
ness occurred in four patients (11%). All problems
occurred immediately after surgery and recovered
completely within several weeks postoperative. During
the use of SARS two patients experienced outflow
problems, which were treated using medication and a
change in the controller parameters. Two patients
suffered from detrusor weakness caused by distension
of the bladder. In one patient progressive sphincter
weakness causes increased incontinence and in one
patient a strong motor response on stimulation was
reported. Technical failures with the external equipment
were cable breaks (16) and transmitter defects (seven),
that is, once per 17 and 38 user-years, respectively.
Technical failures with the internal equipment occurred
four times (11%), that is, once per 66 user-years. The
defects occurred after 43–120 months of controller use.
In three of the four cases, the receivers were replaced
successfully.
Quality of life
In Table 5, the median scores with 10–90th percentiles of
the SIUP for each scale, the SIUP- and QoL index are
presented. The median SIUP index in the study group is
0.84 and in the reference group 1.49 indicating that the
SIUP on the QoL is smaller with the Finetech–Brindley
bladder controller. The median QoL indices for the
study group and the reference group are respectively
0.89 and 0.23, indicating that the overall QoL is rated
higher in the study group.
In Figure 2, the boxplots of the differences of these
median scores between the study group (all patients still
using the bladder controller (32)) and reference group
are presented. As shown, the differences between the two
groups are significant, except for the scale feelings.
Discussion
The objectives of this study were to investigate the long-
term effectiveness of the implanted bladder controller in
SCI patients and in particular the users’ experiences and
the impact of urinary disorders and QoL.
Table 4 Experienced advantages and disadvantages (n=37)
Advantages % Disadvantages %
Decreased infection
rate
68 Other 32
Improved social life 54 None 30
Continence 54 Loss of erection 19
Less incontinence
devices
41 Difficulties in using the
device
11
Improved bowel
function
35 Depending on others 11
Other 19 Deteriorated bowel
function
11
Improved erection 19 Complications 5
Table 5 Median scores of SIUP on QoL in four scales,
overall index and QoL index comparing patients groups with
and without using a bladder controller
Study group
Reference group
Medians 10–90th
percentiles
Medians
Limitations 0.62 0.00–1.99 1.28
Constraints 1.38 0.42–2.73 1.75
Fears 0.63 0.00–2.00 1.60
Feelings 0.80 0.40–1.76 0.91
SIUP index 0.84 0.31–2.00 1.49
QoL index 0.89 0.50–1.63 0.23
Figure 2 Box plots of differences in median scores comparing
patients groups with and without using a bladder controller
(specific impact of urinary problems (SIUP) subscales, overall
SIUP index and quality of life (QoL) index)
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Our long-term results with the bladder controller
with respect to medical and technical complications and
infection rates are similar to the short-term results
presented by others.2,4,6–8 The achieved complete
urinary continence, however, was less than in other
groups. If stress incontinence is included in this
definition, our results are similar to other groups.
The novelty of this study is that together with the
medical benefits the users’ personal experiences and
QoL have been investigated. The main benefits of SARS
experienced by the patients were a decreased infection
rate, improved social life and continence.
The first experiences with the Qualiveen questionnaire
are promising; however, some remarks have to be made.
The questionnaire is easy to complete, none of the
patients did mention any difficulty by completing
the questionnaire. While we described retrospective
data responsiveness of the questionnaire remains
ambiguous.
The results of the Qualiveen questionnaire indicated
that with the bladder controller, the specific impact of
urinary disorders on QoL aspects were reduced, and the
overall QoL improved. The reference group and our
study group are equal with respect to gender, age, time
since lesion and social situation. The major difference
between the two groups is determined by the different
methods used for micturition. The patients in the
reference group used self-catheterisation (41%) or
percussion (28%), the bladder controller was not used.
Another difference between the two groups is that in our
group all patients have complete lesions, whereas in the
reference group about half of the patients had a
complete lesion. This difference could have influenced
the results. Assuming that patients with a complete SCI
in general have a more severe neurogenic bladder
dysfunction, the difference between groups may have
been even more striking when the reference group was
composed of complete SCI patients only. Unfortu-
nately, we were not able to match our patients with the
reference group by lacking crude data of these reference
group of 400 French SCI patients. However, we did
analyse the differences between the median scores on the
Qualiveen items, and they were significant, except for
the subscale feelings.
The Qualiveen questionnaire was developed to
measure disease-specific aspects with respect to limita-
tions, constraints, fears and feelings and general QoL
aspects, suitable for use in SCI patients with urinary
disorders. It is questionable whether this questionnaire
considers all aspects of QoL as defined by the World
Health Organization: ‘QoL is a broad-ranging concept
affected in a complex way by the person’s physical
health, psychological state, level of independence, social
relationships, and their environment’.19 Nevertheless
most existing questionnaires about QoL, as mentioned
before, are generic and not responsive to detect changes
in QoL in SCI patients. In addition, the impact on QoL
of urinary disorders in these patients remains unknown.
Therefore, the Qualiveen questionnaire could be sup-
portive in studies investigating effects of treatment of
urological disorders in SCI patients, but further research
on responsiveness is recommended.
Conclusions
Our results confirm that the bladder controller for
SARS is an adequate technique for bladder management
in patients with a complete SCI over long-term use. It
decreases incontinence and infections, and increases
QoL. These findings support the idea that the bladder
controller is the preferred method of neurogenic
bladder management in a well selected group of SCI
patients.
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